04_Biologics Flashcards

1
Q

Examples of small molecule drugs and biologic drugs?

A

Small molecule drugs: ibrutinib & lenalidomide.
Biologic drugs : dulaglutide & pembrolizumab.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How do the molecular weights of small molecules compare to biologics?

A

Molecular weight of Small molecules inf
Biologics, made of proteins, sup 1,000 g/mol (eg: dulaglutide at 63 kilodaltons & pembrolizumab at 149 kilodaltons)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How does absorption differ between small molecules and biologics?

A

Small molecules : higher membrane permeability (favor oral A)

Biologics: poor membrane permeability (poor F)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the Vd for biologics?

A

Biologics = poor membrane permeability SO are confined to the plasma and interstitial fluids due to their , resulting in a low volume of distribution.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How are biologics cleared from the body?

A

Biologics are typically cleared via intracellular lysosomal proteolytic degradation, with minimal hepatic and renal clearance due to their large size.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Fc recycling and how does it affect biologics?

A

Fc recycling is a process that greatly extends the serum half-life of biologics, especially monoclonal antibodies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why do biologics have longer half-lives compared to small molecules?

A

Due to their small clearance, biologics such as pembrolizumab and dulaglutide have very long half-lives, ranging from days to weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the risks associated with biologics’ high molecular weight?

A

Biologics can interact with the immune system, potentially triggering an immune response that can lead to rapid degradation, inactivation, or even anaphylactic reactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is immunogenicity risk managed in biologics development?

A

Immunogenicity risk is managed by constructing biologics to closely resemble human proteins and monitoring immune responses during pre-clinical and clinical phases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly